LTFS
MRKR icon

Ladenburg Thalmann Financial Services’s Marker Therapeutics MRKR Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-10
Closed -$1K – 5381
2019
Q2 		$1K Hold
10
– – ﹤0.01% 5126
2019
Q1 		$1K Hold
10
– – ﹤0.01% 5086
2018
Q4 		$1K Hold
10
– – ﹤0.01% 5063
2018
Q3 		$1K Sell
10
-50
-83% -$4.29K ﹤0.01% 5010
2018
Q2 		$2K Hold
60
– – ﹤0.01% 4879
2018
Q1 		$2K Buy
60
+50
+500% +$1.77K ﹤0.01% 4879
2017
Q4 		$0 Hold
10
– – ﹤0.01% 5083
2017
Q3 		$0 Buy
+10
New +$316 ﹤0.01% 4984

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Ladenburg Thalmann Financial Services's MRKR Position: Q3 2019 in Review

Ladenburg Thalmann Financial Services sold out of Marker Therapeutics (MRKR) in Q3 2019, closing a stake of 10 shares — an estimated $1K sold.

Ladenburg Thalmann Financial Services first reported a position in MRKR in Q3 2017 and held it in 8 quarters. The position peaked at $2K in Q2 2018. 73 funds tracked by Wall St. Rank hold MRKR as of Q3 2019.

  • Ladenburg Thalmann Financial Services reported no remaining Marker Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Ladenburg Thalmann Financial Services sold 10 Marker Therapeutics shares in Q3 2019, an estimated $1K.
  • Ladenburg Thalmann Financial Services first reported a position in Marker Therapeutics in Q3 2017 and held it in 8 quarters.
  • Ladenburg Thalmann Financial Services's Marker Therapeutics position peaked at $2K in Q2 2018.
  • 73 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q3 2019, filed 14 Nov 2019.